Belite Bio, Inc Belite Bio, Inc

Belite Bio, Inc

BLTE

Pozycja w akcjach #3149
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Cena akcji
$143.80
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$5.74B
Zmiana (1 dzień)
-5.78%
Zmiana (1 rok)
63.95%
Kraj
US
Handel Belite Bio, Inc (BLTE)

Kategoria

Healthcare
EPS dla Belite Bio, Inc (BLTE)
EPS na dzień June 2026 TTM: $-2.76
Według najnowszych raportów finansowych i ceny akcji firmy Belite Bio, Inc, obecny EPS (TTM) wynosi $-2.76. Na koniec roku 2023 firma miała EPS w wysokości $-1.19, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-0.63.
Historia EPS dla Belite Bio, Inc od 2020 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-2.76 133.90%
2024 $-1.18 -0.84%
2023 $-1.19 88.89%
2022 $-0.63 57.50%
2021 $-0.40 -35.48%
2020 $-0.62 0.00%
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -727.54%
US
$-7.98 189.13%
US
$-5.29 91.67%
AU
- -
CH
$27.74 -1,105.07%
NL